UNAIDS welcomes South Africa’s Lenacapavir HIV prevention launch

UNAIDS has welcomed South Africa’s rollout of Lenacapavir as a landmark step in HIV prevention. The injectable is now available at 360 public health facilities across six provinces. The drug has also been added to the national essential medicines list.

South Africa launched the Lenacapavir HIV prevention programme on 6 June 2026. UNAIDS described the development as a landmark achievement for the country. The injectable is currently available at 360 public health facilities in six provinces. Officials have added the drug to South Africa’s essential medicines list. UNAIDS highlighted the rollout as an important measure to expand access to effective HIV prevention options.

Articoli correlati

South Africa has started rolling out the twice-yearly HIV prevention injection lenacapavir, though success depends on managing interactions with common tuberculosis medicines.

Riportato dall'IA

A new NGO report warns that lingering effects of 2025 US Pepfar funding cuts are undermining South Africa's rollout of the six-monthly HIV prevention injection lenacapavir, despite recent US funding restoration efforts and initial shipments. Community infrastructure losses hinder uptake among high-risk groups, even as rollout begins late May.

Agriculture minister john steenhuisen announced that south africa has procured 13.5 million doses of foot and mouth disease vaccines this year with millions more on the way. Nearly 4.4 million animals have been vaccinated as of may 28 as part of the largest such programme in the country’s history. The effort targets 80 percent of the national cattle herd of 14 million to build herd immunity.

Riportato dall'IA

The World Health Organization has declared the Ebola outbreak in the Democratic Republic of the Congo and Uganda a public health emergency of international concern. South African health officials say the risk of spread to the country remains low but stress the need for continued vigilance.

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta